← SynDRA
TENAPANOR
SynDRA canonical compound SYN0038069 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | SLC9A3 |
|---|
| Mechanism of action | sodium/hydrogen exchanger inhibitor |
|---|
All known targets
Mechanisms of action (all sources)
- SLC9A3 INHIBITOR
- Sodium/hydrogen exchanger 3 inhibitor
- sodium/hydrogen exchanger inhibitor
- SLC9A3 MODULATOR
ATC classes
- A06A · DRUGS FOR CONSTIPATION
Cross-references
Synonyms
- tenapanor hydrochloride
- RDX5791
- AZD1722
- AZD-1722
- AZD1722-hydrochloride
- KHK-7791
- RDX-5791
- ibsrela
- KHK7791
- Tenapanor component of rdx-013
- Tenapanor component of rdx013
- TENAPANOR FREE BASE
- UNII-WYD79216A6
- WYD79216A6
- 3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)-N-(26-((3-((S)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl)phenyl)sulfonamido)-10,17-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosyl)benzenesulfonamide
- Tenapanor [USAN:INN]
- Tenapanor(free base)
- GTPL8449
- CHEMBL3304485
- SCHEMBL15267600
- DTXSID40154016
- BCP24892
- BCP28554
- EX-A2506
- RDX-013 COMPONENT TENAPANOR
- RDX013 COMPONENT TENAPANOR
- AZD 1722
- tenapanorum
- RefChem:58054
- DTXCID9076507
- Tenapanor free base
- Tenapanor [INN]
- C50H66Cl4N8O10S2
- MFCD28386333
- TENAPANOR [MI]
- Tenapanor (USAN/INN)
- TENAPANOR [USAN]
- TENAPANOR [WHO-DD]
Reported adverse events
- Dizziness
- Flatulence
- Hypersensitivity
Look up TENAPANOR in the interactive SynDRA portal →